Targeted degradation of CD147 proteins in melanoma

Bioorg Chem. 2020 Dec:105:104453. doi: 10.1016/j.bioorg.2020.104453. Epub 2020 Nov 4.

Abstract

CD147 is a transmembrane glycoprotein and a member of immunoglobulin superfamily, is strongly expressed in melanoma cells. CD147 has a pivotal role in tumor development. Therefore, it is a potential drug target for melanoma. In this article, we report the discovery of the first CD147 protein proteolysis targeting chimeras (PROTACs) derived from the natural product pseudolaric acid B (PAB). The representative compound 6a effectively induced degradation of CD147 and inhibited melanoma cells in vitro and in vivo. 6a could be used as the novel type of anticancer agent or as a part of the molecular biology research toolkit used in the gain-of-function study of the dynamic roles of CD147 in cancer networks.

Keywords: CD147; Degradation; Melanoma; PROTAC; Pseudolaric Acid B.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkylation
  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Basigin* / metabolism
  • Cell Line, Tumor
  • Cell Movement
  • Diterpenes* / chemical synthesis
  • Diterpenes* / pharmacology
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Melanoma* / drug therapy
  • Mice
  • Mice, Nude
  • Molecular Structure
  • Neoplasms, Experimental
  • Proteolysis*
  • Wound Healing / drug effects

Substances

  • Antineoplastic Agents
  • Basigin
  • Diterpenes
  • pseudolaric acid B